Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_19
Snippet: We next performed simulations of therapy at very early timepoints during infection at and prior to peak viral load. Most infected people are pre-symptomatic at this stage so these model realizations may most closely reflect implementation of a post exposure prophylaxis strategy in which some people are already in the very early stages of infection at the time of first dose. Under this scenario, extremely potent (EC50=0.8 uM) therapies at day 2 an.....
Document: We next performed simulations of therapy at very early timepoints during infection at and prior to peak viral load. Most infected people are pre-symptomatic at this stage so these model realizations may most closely reflect implementation of a post exposure prophylaxis strategy in which some people are already in the very early stages of infection at the time of first dose. Under this scenario, extremely potent (EC50=0.8 uM) therapies at day 2 and 0 of infection resulted in immediate viral suppression (Fig. 4c, d) . With early, low or moderate potency treatment, the model predicted therapeutic failure with persistent SARS CoV-2 shedding due to insufficient early immunity against the virus (Fig. 4d) .
Search related documents:
Co phrase search for related documents- dose time and infected people: 1
- dose time and post exposure: 1, 2, 3, 4
- early immunity and infected people: 1, 2
- early immunity and infection early stage: 1, 2, 3, 4, 5, 6, 7
- early immunity and post exposure: 1
- early stage and infected people: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- early stage and infection early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- early stage and post exposure: 1, 2, 3, 4, 5
- early stage and potency treatment: 1
- early stage and SARS shed: 1, 2
- infected people and post exposure: 1, 2, 3, 4, 5
- infected people and prior viral load peak: 1
- infected people and prior viral load peak infection: 1
- infected people and SARS shed: 1, 2, 3, 4
- infection early stage and potency treatment: 1
Co phrase search for related documents, hyperlinks ordered by date